Australia regenerative medicine market is anticipated to register growth with an impressive CAGR in the forecast period, 2023-2027, on the account of advancing medicines and growing expenses over advancement of the pharmaceutical products. Increasing evolution in pharmaceutical sector to design advanced drugs, and various other methods to better the existing treatment along with finding curative medicines for the unknown diseases, are anticipated to drive the growth of the Australia regenerative medicine market in the upcoming five years.
Regenerative medicines are a class of drugs that help in the process of replacing, engineering or regenerating human cells or animal cells. The drugs help in restoring the normal functioning of the cells. To restore the functions, regenerative medicines stimulate the body’s own repair system to heal the irreparable tissues and organs. The regenerative medicine has potential that can be used for artificial generation of tissues and organs in laboratory that can later be implanted safely in case the body is unable to heal in certain conditions. Various biomedical techniques and clinical therapies are involved with regenerative medicine like cell therapy, immunomodulation therapy, and tissue engineering.
Bio-medical Advances Drive Market Growth
Regenerative medicines are advanced pharmaceuticals that undergo consistent research and product development such that better healthcare and patient care services are provided. Biomedical methods like cell therapy, immunomodulation therapy, and tissue engineering are increasing with the advancement in medicine and driving the growth of the Australia regenerative medicine market in the upcoming five years.
Moreover, increasing investment in these biomedical procedures and their research also aid the growth of the Australia regenerative medicine market in the next five years. Australian Government Department of Industry, Innovation and Science have funded Cooperative Research Center Program and amount of USD60 million through CTM CRC to develop integrated cost effective, and accessible cell therapies that have further revolutionized regenerative medicine.
Chronic Diseases Surges Demands For Regenerative Medicine
Increase in the instances of various neurological diseases and cancer, that are chronic and require advanced medicinal approach further support the growth of the Australia regenerative medicine market in the upcoming five years. Alzheimer’s disease, Parkinson’s disease, cardiovascular disorders (CVDs), osteoporosis and spinal cord injuries are being treated with regenerative medicine and thus supporting market growth.
Also, rising geriatric population in the country that is prone to diseases like musculoskeletal, oncological, dermatological and cardiological disorders are aiding the growth of the Australia regenerative medicine market in the next five years.
Click here to download the sample
Market Segmentation
The Australia regenerative medicine market is segmented by type, application, end user, competitional landscape, and regional distribution.
Market segments on the basis of end user, is further divided between academic and commercial end users. The market analysis also studies the regional segmentation to devise regional market segmentation, divided among Northern territory region, New South Wales region, Victoria region, Western Australia region, Queensland region, Tasmania region, and the South Australia region.
Company Profile
Cell Therapies Pty Ltd., Hudson Institute, Orthocell Ltd., Q-Gen Cell Therapeutics, Westmead Viral Vector Facility, Sydney Cell & Gene Therapies, Auspep Holdings Ltd., Luina Bio Pty Ltd.
| Attribute | Details |
| Base Year | 2021 |
| Historical Data | 2017 – 2020 |
| Estimated Year | 2022 |
| Forecast Period | 2023 – 2027 |
| Quantitative Units | Revenue in USD Million, and CAGR for 2017-2021 and 2022-2027 |
| Report coverage | Revenue forecast, company share, competitive landscape, growth factors, and trends |
| Segments covered | · Type · Application · End User |
| Regional scope | Northern territory region, New South Wales region, Victoria region, Western Australia region, Queensland region, Tasmania region, and the South Australia region. |
| Key companies profiled | Cell Therapies Pty Ltd., Hudson Institute, Orthocell Ltd., Q-Gen Cell Therapeutics, Westmead Viral Vector Facility, Sydney Cell & Gene Therapies, Auspep Holdings Ltd., Luina Bio Pty Ltd. |
| Customization scope | 10% free report customization with purchase. Addition or alteration to country, regional & segment scope. |
| Pricing and purchase options | Avail customized purchase options to meet your exact research needs. Explore purchase options |
| Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
